https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-12-02 / Expert Rev Clin Immunol 2016;12(2):91-4
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-12-02 / Expert Rev Clin Immunol 2016;12(2):91-42015-12-02 00:00:002019-02-15 08:48:04HIV immunotherapy comes of age: implications for prevention, treatment and cure
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-11-15 / World J Gastrointest Oncol 2015 Nov;7(11):338-46
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-11-15 / World J Gastrointest Oncol 2015 Nov;7(11):338-462015-11-15 00:00:002015-11-15 00:00:00Immunotherapeutic approaches in biliary tract carcinoma: Current status and emerging strategies
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-11-05 / Cancer 2016 Feb;122(3):367-77
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-11-05 / Cancer 2016 Feb;122(3):367-772015-11-05 00:00:002015-11-05 00:00:00Immunotherapy in hepatocellular carcinoma: Primed to make a difference?
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-10-20 / Oncotarget 2015 Oct;6(32):33781-90
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-10-20 / Oncotarget 2015 Oct;6(32):33781-902015-10-20 00:00:002019-02-15 08:45:06Dendritic cell vaccination with a toll-like receptor agonist derived from mycobacteria enhances anti-tumor immunity
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-10-15 / BMC Cancer 2015 Oct;15:708
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-10-15 / BMC Cancer 2015 Oct;15:7082015-10-15 00:00:002019-02-15 08:48:27Improving immunological tumor microenvironment using electro-hyperthermia followed by dendritic cell immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-10-01 / Pharmacol. Rev. 2015 Oct;67(4):731-53
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-10-01 / Pharmacol. Rev. 2015 Oct;67(4):731-532015-10-01 00:00:002019-02-15 08:45:13Dendritic Cells as Pharmacological Tools for Cancer Immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-10-01 / Drug Discov Ther 2015 Oct;9(5):363-71
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-10-01 / Drug Discov Ther 2015 Oct;9(5):363-712015-10-01 00:00:002015-10-01 00:00:00Immunotherapy for hepatocellular carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-10-01 / J. Immunother. 2015 Oct;38(8):330-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-10-01 / J. Immunother. 2015 Oct;38(8):330-92015-10-01 00:00:002019-02-15 08:51:17Lenalidomide Synergistically Enhances the Effect of Dendritic Cell Vaccination in a Model of Murine Multiple Myeloma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-09-29 / Oncotarget 2015 Sep;6(29):27751-62
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-09-29 / Oncotarget 2015 Sep;6(29):27751-622015-09-29 00:00:002019-02-15 08:52:37Pancreatic adenocarcinoma upregulated factor serves as adjuvant by activating dendritic cells through stimulation of TLR4
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-09-15 / Oncotarget 2015 Sep;6(27):23462-79
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-09-15 / Oncotarget 2015 Sep;6(27):23462-792015-09-15 00:00:002019-02-15 08:52:37A pancreatic tumor-specific biomarker characterized in humans and mice as an immunogenic onco-glycoprotein is efficient in dendritic cell vaccination
